{"nctId":"NCT00438659","briefTitle":"Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ","startDateStruct":{"date":"2007-08"},"conditions":["Breast Cancer","Dermatologic Complications","Radiation Toxicity","Skin Reactions Secondary to Radiation Therapy"],"count":176,"armGroups":[{"label":"Mometasone","type":"EXPERIMENTAL","interventionNames":["Drug: mometasone furoate"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo"]}],"interventions":[{"name":"mometasone furoate","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed diagnosis of primary invasive breast cancer or ductal carcinoma in situ\n* Planning to undergo ≥ 5 weeks of continuous definitive or adjuvant external-beam radiotherapy to 1 of the following sites:\n\n  * Whole breast (as part of breast-conservation therapy)\n  * Chest wall (as part of post-mastectomy irradiation)\n\n    * Treatment of regional lymph nodes (i.e., axillary, supraclavicular, or internal mammary) allowed\n* Must meet the following criteria for planned radiotherapy:\n\n  * Planned total radiation dose ≥ 5,000 Gy and daily radiation dose between 1.75 and 2.12 Gy\n  * No planned split-course radiotherapy\n  * No partial breast treatment, defined as treatment of \\< 75% of the breast parenchyma\n  * Intensity-modulated radiotherapy planning and delivery, conventional radiotherapy, or 3-dimensional radiotherapy techniques allowed\n* Must be entered on study within 7 days prior to beginning radiotherapy\n\n  * Must start study drug prior to receiving the third radiotherapy fraction\n* No preexisting skin breakdown within the planned radiotherapy field at the time of study entry\n* No bilateral breast cancer treatment\n* No inflammatory carcinoma of the breast\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Male or female\n* Menopausal status not specified\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Able to complete questionnaires independently or with assistance\n* No known allergy or hypersensitivity to mometasone furoate (Elocon® or generic cream), imidazolidinyl urea, or formaldehyde\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior radiotherapy to the planned radiotherapy treatment area\n* No concurrent or planned leukotriene inhibitors, including the following:\n\n  * Zafirleukast\n  * Monteleukast\n  * Zileuton\n* No concurrent or planned use of any prescription or over-the-counter medications containing hydrocortisone or any other cortisone or steroid-containing preparations (systemic, local, or topical) including, but not limited to, the following creams or ointments:\n\n  * Cortaid®\n  * Cortizone 10®\n  * Tucks®\n  * Preparation H®\n* No other concurrent topical agents (e.g., lotions, aloe vera) to radiotherapy field during study treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Maximum Grade of Radiation Dermatitis by Treatment Arm.","description":"Maximum grade of radiation dermatitis as measured by the Common Terminology Criteria (CTCAE) for Adverse Events (AE), Version 3.0. Grade 1 (Mild AE), Grade 2 (Moderate AE), Grade 3 (Severe AE), Grade 4 (Life-threatening or disabling AE), Grade 5 (Death related to AE).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Severe ( Grade >=3) Radiation Dermatitis","description":"To compare incidence of severe (Grade ≥ 3) radiation dermatitis as measured by the CTCAE v3.0 for the mometasone and placebo arms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Skin Toxicity as Measured by the Skin Toxicity Assessment Tool","description":"Mean of the Maximum Patient Reported Skin Toxicity Assessment Tool (STAT) per patient on a 0 to 5 scale during radiation treatment. Lower scores indicate less toxicity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"1.69"},{"groupId":"OG001","value":"2.1","spread":"1.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"1.53"},{"groupId":"OG001","value":"2.2","spread":"1.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.36"},{"groupId":"OG001","value":"1.4","spread":"1.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.57"},{"groupId":"OG001","value":"2.5","spread":"1.61"}]}]}]},{"type":"SECONDARY","title":"Skin Toxicity as Measured by a Dermatologic Quality-of-life Instrument (Skindex-16).","description":"Patient-Reported Mean of the Maximum Total a Skindex-16 Toxicity Score per patient on a 0-6 scale during radiation treatment (Lower score indicates less toxicity).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"1.24"},{"groupId":"OG001","value":"1.7","spread":"1.35"}]}]}]},{"type":"SECONDARY","title":"Duration of Severe (Grade ≥ 3) Radiation Dermatitis as Measured by the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. This Analysis Was Not Completed Due to Too Little Incidence of the Dermatitis.","description":"To compare time to onset and duration of severe (Grade ≥ 3) radiation dermatitis as measured by the CTCAE v3.0 for the mometasone and placebo arms. This analysis was not completed due to too little incidence of the dermatitis.","classes":[]},{"type":"SECONDARY","title":"Overall Quality of Life (QOL) as Measured by Linear Analogue Self-Assessment (LASA)","description":"Patient completed QOL assessment was the Linear Analogue Self-Assessment (LASA). This instrument consisted of 6 questions with responses ranging from 0 (poor QOL) to 100 (best QOL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":"16"},{"groupId":"OG001","value":"82","spread":"19"}]}]}]},{"type":"SECONDARY","title":"QOL Domains as Measured by LASA","description":"Mean scores of Linear Analogue Sef-Assessment (LASA) Mental, physical, emotional, social, spiritual wel-being on a 0 (as bad as it can be) to 100 (as good as it can be) scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":"15"},{"groupId":"OG001","value":"84","spread":"18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":"17"},{"groupId":"OG001","value":"79","spread":"19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":"16"},{"groupId":"OG001","value":"80","spread":"19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":"19"},{"groupId":"OG001","value":"77","spread":"24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":"14"},{"groupId":"OG001","value":"84","spread":"21"}]}]}]},{"type":"SECONDARY","title":"Adverse Events Assessed Clinically by NCI CTCAE v3.0","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events Reported by the Patient in the Symptom Experience Diary (SED).","description":"Maximum SED score during radiation treatment per patient on a 0 to 10 scale (lower score is better)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"3.52"},{"groupId":"OG001","value":"6.8","spread":"3.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"3.33"},{"groupId":"OG001","value":"3.1","spread":"3.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"2.65"},{"groupId":"OG001","value":"1.6","spread":"3.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"2.77"},{"groupId":"OG001","value":"1.4","spread":"2.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"3.38"},{"groupId":"OG001","value":"4.0","spread":"3.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"3.29"},{"groupId":"OG001","value":"2.4","spread":"3.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"3.06"},{"groupId":"OG001","value":"5.0","spread":"3.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"3.12"},{"groupId":"OG001","value":"2.1","spread":"2.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"2.8"},{"groupId":"OG001","value":"1.5","spread":"2.66"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":84},"commonTop":["Dermatitis radiation","Pruritus","Thermal burn","Skin disorder","Skin hypopigmentation"]}}}